What is KLOW blend?
A peptide blend combines more than one peptide together to produce additive, and sometimes synergistic, effects.
The KLOW blend is a combination of four peptides: GHK-Cu, KPV, TB4 (or TB-500), and BPC-157.
What is in the KLOW blend?
KLOW contains the following peptides:
BPC-157 is a peptide that influences multiple biological pathways involved in healing and tissue repair. It interacts with the body’s nitric oxide system to help regulate blood flow and inflammation, supports the formation of new blood vessels (angiogenesis), and promotes cellular migration to help cells move to injured areas and rebuild damaged structures. It has also shown potential in protecting nerves and supporting nerve regeneration in animal models.
Thymosin beta 4 (TB4) is a naturally occurring peptide found in nearly every cell in the human body, encoded by a gene on the X chromosome. Its primary role is to bind to actin, a key microfilament in the cytoskeleton, helping reorganize the cell’s structural framework and influence how cells move. Research has shown that TB4 plays an important role in tissue repair, helping cells migrate to the site of injury so they can rebuild and heal damaged tissue. TB-500 can be used instead of TB4 in the KLOW blend, and it offers similar advantages.
GHK-Cu is a naturally occurring copper peptide found in human plasma, saliva, and urine. It has been studied extensively for its role in tissue repair, skin health, and anti-inflammatory processes. Interest in GHK-Cu has grown due to its apparent ability to signal regeneration without overstimulating growth pathways.
KPV is a short peptide composed of three amino acids—lysine, proline, and valine. KPV has drawn interest for its potent anti-inflammatory properties. It is derived from a larger naturally occurring hormone called alpha-melanocyte–stimulating hormone (α-MSH). The KPV portion of α-MSH plays a role in immune regulation and inflammation control. Researchers discovered that KPV retains much of α-MSH’s anti-inflammatory activity without affecting pigmentation or hormonal balance.
When combined together, the components of KLOW promote healing of injured tissues in a synergistic fashion, suppress inflammation, and maintain skin health.
What is KLOW Blend Used For?
- Wound healing and tissue repair, especially muscles, tendons, ligaments
- Reducing inflammation
- Joint support: By supporting connective tissue repair, this combination may play a role in joint recovery following injury.
- Nerve protection: Experimental models suggest potential benefits in nerve healing and protection after trauma.
- Wound healing
- Skin rejuvenation
Side Effects of KLOW Blend
Limited data shows that BPC-157, TB4, GHK-Cu, and KPV individually are well-tolerated with minimal side effects. Most of the side effects have been due to the injection rather than the peptides. Please see the pages for BPC-157, TB4, KPV, and GHK-Cu for more details.
The most common side effect is injection site pain or reactions, most often attributed to the GHK-Cu component.
KLOW Blend Dosing Protocol (for Research)
KLOW formulations usually contain the peptides in the following amounts:
GHK-Cu: 50 mg
BPC-157: 10 mg
TB4 (or TB-500): 10 mg
KPV: 10 mg
The total is therefore 80 mg. The suggested research protocol below is based on the composite vial (80 mg), and not for the individual doses:
| Phase | Dose & frequency |
|---|---|
| Week 1 | 2 mg daily (2 mg total, which adds up to 1.25 mg GHK-Cu and 0.25 mg of each of KPV, BPC-157, and TB4 (or TB-500)) |
| Week 2 and beyond | 4 mg daily (4 mg total, which adds up to 2.5 mg GHK-Cu and 0.50 mg of each of KPV, BPC-157, and TB4 (or TB-500)) |
Shown for education. A licensed clinician should set any actual dose. Compare protocols across peptides in the peptide dosage chart.
Common questions about KLOW blend
What is KLOW blend?
A peptide blend combines more than one peptide together to produce additive, and sometimes synergistic, effects. The KLOW blend is a combination of four peptides: GHK-Cu, KPV, TB4 (or TB-500), and BPC-157.
What is KLOW blend used for?
Areas studied include: Wound healing and tissue repair; Reducing inflammation; Joint support; Nerve protection; Wound healing; Skin rejuvenation.
What are the side effects of KLOW blend?
Limited data shows that BPC-157, TB4, GHK-Cu, and KPV individually are well-tolerated with minimal side effects. Most of the side effects have been due to the injection rather than the peptides.
What is the dosage of KLOW blend?
One commonly referenced research protocol is: Week 1: 2 mg daily (2 mg total, which adds up to 1.25 mg GHK-Cu and 0.25 mg of each of KPV, BPC-157, and TB4 (or TB-500)); Week 2 and beyond: 4 mg daily (4 mg total, which adds up to 2.5 mg GHK-Cu and 0.50 mg of each of KPV, BPC-157, and TB4 (or TB-500)). Shown for education only; a licensed clinician should set any actual dose. See the dosing table.
How do you mix (reconstitute) KLOW blend?
Wipe the vial tops with alcohol, add bacteriostatic water slowly so it runs down the inside of the glass, then roll the vial gently until the powder dissolves; don’t shake it. See the step-by-step guide with diagrams for the pen and syringe methods.
How much bacteriostatic water do you add to KLOW blend?
There is no single correct amount. We recommend 2.1 mL: about 0.1 mL is lost during transfer, leaving roughly 2.0 mL of usable solution. You can add more or less (most peptide vials hold up to 3 mL); just enter the amount in the dose calculator. See the step-by-step mixing guide.
Is KLOW blend FDA-approved?
No. KLOW blend is not FDA-approved in the US (status as of October 2026).
References
- Sikiric P, et al. Stable gastric pentadecapeptide BPC-157: novel therapy in gastrointestinal and extra-intestinal healing. Curr Pharm Des. 2011;17(16):1612–1632. View source
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19:969-88. doi: 10.1163/156856208784909435. View source
- Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988 Oct 10;238(2):343-6. doi: 10.1016/0014-5793(88)80509-x. View source
- Pickart L, et al. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018 Jul 7;19(7):1987. doi: 10.3390/ijms19071987. View source
- Seiwerth S, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014;20(7):1121-5. doi: 10.2174/13816128113199990421. PMID: 23782145. View source
- Luger TA, Brzoska T. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2007;66 Suppl 3(Suppl 3):iii52-5. doi: 10.1136/ard.2007.079780. View source
- Xue B, et al. Structural basis of thymosin-β4/profilin exchange leading to actin filament polymerization. Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):E4596-605. View source
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134:166-78. doi: 10.1053/j.gastro.2007.10.026. Epub 2007 Oct 17. View source
- Delgado R, et al. Melanocortin peptides inhibit production of proinflammatory cytokines and nitric oxide by activated microglia. J Leukoc Biol. 1998 Jun;63(6):740-5. doi: 10.1002/jlb.63.6.740. View source
- Sosne G, et al. 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. 2022 Dec 29;24(1):554. View source
- Wang X, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021 Sep;25(17):8222-8228. View source